GILD AI Stock Analysis – Buy, Hold, or Avoid?
Gilead Sciences, Inc. (GILD)
Gilead Sciences (GILD) offers a compelling long-term investment case, underpinned by robust fundamentals, fair valuation, and improving sentiment, despite moderate risk and near-term technical consolidation. While short-term technicals suggest caution, the company’s strong pipeline, consistent earnings beats, and expanding oncology presence support a bullish outlook for medium- and long-term investors. The risk/reward profile is attractive, especially on pullbacks near support.
Fundamentals
Gilead Sciences (GILD) shows a stable fundamental profile with a recent return to robust profit margins and solid earnings growth following a period of volatility. The company maintains strong cash generation and high margins, with recent quarterly results consistently outperforming analyst expectations. Despite modest top-line growth, its earnings expansion and profitability profile enhance investment appeal.
Financial Highlights
- Revenue
- Net Income
- Net Margin (%)
Revenue
4.70% YoY
Q4 2025
Net Income
22.43% YoY
Q4 2025
Net Margin
Q4 2025
Growth Metrics
Revenue Growth YoY
Latest Quarter: Q4 2025
Net Income Growth YoY
Latest Quarter: Q4 2025
Revenue Per Share Growth YoY
Latest Quarter: Q4 2025
EPS Growth YoY
Latest Quarter: Q4 2025
Book Value Per Share Growth YoY
Latest Quarter: Q4 2025
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7.9B | 7.8B | 7.1B | 6.7B | 7.6B | 7.5B | 7.0B | 6.7B |
| Revenue Growth YoY | +4.70% | +2.97% | +1.84% | -0.28% | +6.40% | +7.02% | +5.36% | +5.26% |
| Net Income | 2.2B | 3.1B | 2.0B | 1.3B | 1.8B | 1.3B | 1.6B | -4.2B |
| Net Income Growth YoY | +22.43% | +143.58% | +21.44% | +131.53% | +24.77% | -42.52% | +54.45% | -512.87% |
| EPS | $1.76 | $2.46 | $1.57 | $1.06 | $1.43 | $1.00 | $1.29 | -$3.34 |
| EPS Growth YoY | +23.08% | +146.00% | +21.71% | +131.74% | +24.35% | -42.86% | +53.57% | -512.35% |
Profitability Metrics
Gross Margin
TTM
Operating Margin
TTM
Net Margin
TTM
Return on Equity
TTM
Return on Assets
TTM
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.84% | 79.80% | 78.80% | 76.90% | 79.11% | 79.14% | 77.79% | 76.79% |
| Operating Margin | 37.40% | 42.82% | 34.94% | 33.55% | 32.40% | 11.77% | 38.03% | -64.64% |
| Net Margin | 27.55% | 39.28% | 27.68% | 19.72% | 23.56% | 16.61% | 23.21% | -62.37% |
| Return on Equity (ROE) | 9.65% | 14.17% | 9.96% | 6.86% | 9.22% | 6.78% | 8.83% | -23.78% |
| Return on Assets (ROA) | 6.47% | 9.46% | 6.80% | 4.57% | 5.80% | 4.88% | 7.19% | -16.99% |
Technical Analysis
GILD is currently in an advancing phase with a mixed but overall bullish technical backdrop. The stock trades just below its 50-day SMA with clear support around $138-$136 and resistance near $144-$147. Momentum is neutral with weak trend strength, indicating a potential consolidation before a decisive move.
No extreme reading
Mixed signals
Range-bound market
Watching for cross
Key Technical Values
Price with Moving Averages
50-day, 150-day and 200-day simple moving averages
Relative Strength Index
Momentum oscillator measuring speed and magnitude of price changes
RSI (14)
Earnings
Gilead Sciences (GILD) shows a stable fundamental profile with a recent return to robust profit margins and solid earnings growth following a period of volatility. The company maintains strong cash generation and high margins, with recent quarterly results consistently outperforming analyst expectations. Despite modest top-line growth, its earnings expansion and profitability profile enhance investment appeal.
Latest Earnings
Q4 2025 Earnings (Dec 31, 2025)
Earnings Per Share (EPS)
Actual
$1.86
Estimated
$1.81
Surprise
+$0.05
Surprise %
+2.76%
Revenue
Actual
$7.93B
Estimated
$7.69B
Surprise
+$234.64M
Surprise %
+3.05%
Historical Earnings
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share | ||||||||
| EPS (Actual) | $1.86 | $2.47 | $2.01 | $1.81 | $1.90 | $2.02 | $2.01 | $-1.32 |
| EPS (Estimated) | $1.81 | $2.13 | $1.96 | $1.78 | $1.74 | $1.53 | $1.61 | $-1.49 |
| EPS Surprise | +$0.05 | +$0.34 | +$0.05 | +$0.03 | +$0.16 | +$0.49 | +$0.40 | +$0.17 |
| % Diff | +2.8% | +16.0% | +2.6% | +1.7% | +9.2% | +32.0% | +24.8% | +11.4% |
| Revenue | ||||||||
| Revenue (Actual) | $7.93B | $7.77B | $7.08B | $6.67B | $7.57B | $7.55B | $6.95B | $6.69B |
| Revenue (Estimated) | $7.69B | $7.45B | $6.98B | $6.81B | $7.15B | $7.02B | $6.7B | $6.36B |
| Revenue Surprise | +$234.64M | +$323.62M | +$99.5M | -$143.87M | +$416.55M | +$529.36M | +$246.47M | +$328.91M |
| % Diff | +3.1% | +4.3% | +1.4% | -2.1% | +5.8% | +7.5% | +3.7% | +5.2% |
Valuation
Gilead Sciences is showing steady financial performance with moderate revenue and earnings growth, supported by a strong gross margin and effective operating efficiencies. Valuation metrics indicate the stock trades at a reasonable premium relative to broad healthcare averages but remain justified by solid profitability and growth prospects primarily driven by its HIV and oncology portfolios. Analyst sentiment is positive, reaffirming a bullish outlook with price targets implying upside potential over the next 12 months.
Valuation Metrics
Price to Earnings
TTM
Price to Sales
TTM
Price to Book
TTM
Enterprise Value to EBITDA
TTM
Enterprise Value to Revenue
TTM
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Price to Earnings | 17.46 | 11.30 | 17.61 | 26.54 | 16.16 | 20.86 | 13.26 | -5.45 |
| Price to Sales | 19.24 | 17.76 | 19.49 | 20.94 | 15.23 | 13.86 | 12.31 | 13.59 |
| Price to Book | 6.74 | 6.41 | 7.02 | 7.29 | 5.96 | 5.66 | 4.68 | 5.18 |
| Enterprise Value to EBITDA | 72.64 | 33.95 | 46.78 | 60.13 | 42.65 | 65.16 | 35.58 | -31.44 |
| Enterprise Value to Revenue | 21.38 | 20.03 | 22.29 | 23.49 | 17.52 | 16.27 | 15.27 | 16.66 |
Sentiment & Analyst Ratings
Gilead Sciences (GILD) sentiment is generally positive, supported by a strong analyst consensus favoring buy or moderate buy ratings and firm price targets in the $155-$180 range. Recent strategic acquisitions, strong quarterly earnings beats, and dividend increases bolster optimism, although some concerns remain around select revenue segments and guidance nuances. Social media sentiment reflects a cautious but engaged retail investor base, focused on Gilead's shift towards oncology and autoimmune therapies.
Analyst Recommendations
Risk Assessment
Gilead Sciences shows a moderate-risk financial profile characterized by stable liquidity and manageable debt levels. The company is navigating ongoing regulatory and competitive pressures, particularly in its core HIV franchise and emerging oncology portfolio, while maintaining solid earnings and cash flow to support debt servicing. Investors should weigh Gilead's steady fundamentals against sector-wide pricing reforms and evolving market competition.
Liquidity & Solvency
Current Ratio
Latest Quarter: Q4 2025
Quick Ratio
Latest Quarter: Q4 2025
Debt-to-Equity
Latest Quarter: Q4 2025
Debt-to-Assets
Latest Quarter: Q4 2025
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Liquidity Metrics | ||||||||
| Current Ratio | 1.68 | 1.45 | 1.32 | 1.37 | 1.60 | 1.26 | 1.14 | 1.08 |
| Quick Ratio | 1.31 | 1.31 | 1.15 | 1.23 | 1.45 | 1.10 | 0.95 | 0.94 |
| Solvency Metrics | ||||||||
| Debt-to-Equity | 1.09 | 1.16 | 1.27 | 1.30 | 1.41 | 1.26 | 1.28 | 1.44 |
| Debt-to-Assets | 0.42 | 0.43 | 0.45 | 0.44 | 0.46 | 0.43 | 0.44 | 0.45 |
Liquidity Assessment
Current Ratio: 1.68(Strong)
Quick Ratio: 1.31(Strong)
The company has strong liquidity with sufficient short-term assets to cover liabilities.
Solvency Assessment
Debt-to-Equity: 1.09(High)
Debt-to-Assets: 0.42(Moderate)
The company has relatively high debt levels, which may increase financial risk in economic downturns.
Frequently Asked Questions about GILD
AI Answers: Common Questions About GILD
Get AI-powered answers to the questions investors ask most about Gilead Sciences, Inc.
Gilead is a good buy for medium- and long-term investors: the stock trades at a reasonable P/E of 17.05 and EV/EBITDA of 15-16, with strong gross (87%) and operating (40%) margins. Analyst targets ($155-$180) imply 12-30% upside from current levels, and fundamentals are robust. Short-term traders should wait for a technical breakout above $144.
There is no compelling reason to sell unless your timeframe is very short and you seek to avoid near-term consolidation. Fundamentals are improving, valuation is fair, and sentiment is positive; only short-term traders might consider trimming if support at $136 fails.
The biggest risks are patent cliffs for key HIV drugs, regulatory pricing reforms, and increased competition from biosimilars/generics. Debt-to-equity is 1.1 (moderate), and debt represents 42% of assets, but interest coverage is strong (>11x), so financial risk is manageable.
Technical resistance is at $144.33 (short-term), $147.80 (intermediate), and $156 (52-week high); downside support is $138-$136 and $133. Analyst targets cluster at $155-$180, suggesting meaningful upside if the company continues to execute.
GILD is fairly valued: P/E is 17.05, EV/EBITDA is 15-16, and return on equity is above 37%. These multiples are in line with sector averages and justified by the company’s profitability and growth outlook, with no signs of overvaluation.
Fundamentals are very strong: gross margin is 87%, operating margin is 40%, and net margin is 29%. EPS more than doubled YoY, revenue grew 24% in 2025, and the balance sheet is solid with robust cash flow and manageable debt.
Technical analysis is neutral: price is consolidating just below the 50-day SMA ($144.86), RSI is neutral at 45, and support sits at $138-$136. Wait for a breakout above $144 for momentum trades, or accumulate near support for longer-term positions.
Key catalysts include upcoming earnings releases, FDA decisions and product launches in oncology and autoimmune, and further dividend increases or strategic acquisitions. Positive surprises in these areas could drive the next leg higher.
Want a Personalized Answer?
Get AI-powered insights tailored to your risk tolerance and investment goals.